Merck KGaA, AMCM/EOS co-operate in 3D printing of tablets
A cooperation agreement between German pharma firm Merck KGaA and additive manufacturing specialist AMCM on 3D printing of tablets could eventually lead to scalable active pharmaceutical ingredient (API) formulation and faster, cheaper production, the two companies said Thursday.
The pharma industry sees much potential in 3D printing technology as it offers potential solutions to the challenges around producing personalised medicines and tailored dosages. AMCM offers customized additive manufacturing solutions and is a sister company of 3D printing leader EOS.
The partnership will initially target GMP-compliant tablet formulation development and production for clinical trials before extending to commercial manufacturing services.
“Our partnership with AMCM/EOS could revolutionize the way tablets are produced. It will be a massive move towards digitalization of the industry,” said Isabel de Paoli, chief strategy officer at Merck. “Our goal is to develop the industrial application of this technology, which we will make available for clinical trials first, and then move to full digital solutions at commercial scale.”
Marie Langer, CEO of EOS said the co-operation combines Merck’s formulation and excipient expertise with AMCM's additive manufacturing know-how to "help make drug development more flexible and faster.”
The basis of the technology is using powder bed fusion methods -- whereby a laser melts and fuses powder together layer by layer -- to simplify the clinical development process of drugs, the firms said.
It is hoped that 3D printing will make API formulation scalable while avoiding costly reformulations throughout pharmaceutical development and commercial production processes.
According to the two companies, the vision is to achieve flexible and sustainable local tablet production that meets specific market requirements as well as adapting to patient needs.
A project teams at Merck's Innovation Center at its Darmstadt headquarters is working on next-generation tablet manufacturing through 3D printing.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance